AI assistant
KIORA PHARMACEUTICALS INC — Director's Dealing 2018
Jun 13, 2018
35256_dirs_2018-06-13_82ebcb19-6e65-4eb7-8ad9-b8a718a939c0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2018-06-07
Reporting Person: Wirostko Barbara (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-07 | Common Stock | A | 2215 | $0.52 | Acquired | 52915 | Indirect |
| 2018-06-07 | Common Stock | A | 9600 | $0.52 | Acquired | 249997 | Direct |
| 2018-06-08 | Common Stock | A | 7000 | $0.54 | Acquired | 59915 | Indirect |
Footnotes
F1: The Form 4 previously filed on June 11, 2018 inadvertently misclassified the 2,215 shares purchased on June 7, 2018 and 7,000 shares purchased on June 8, 2018 as being beneficially owned directly by the reporting person instead of indirectly, and inadvertently omitted the purchase of 9,600 shares by the reporting person on June 7, 2018, which are beneficially owned directly. This amendment corrects that error to add the omitted transaction from June 7, 2018 and to reflect the correct number of shares beneficially owned by the reporting person, both directly and indirectly, after the reported transaction.